Next generation compounds(Tranquis Therapeutics)(Next generation compounds(Tranquis Therapeutics)) - 在研适应症：免疫系统疾病，神经系统疾病_专利_临床

概要

基本信息

药物类型

未知

别名-

靶点-

作用机制-

治疗领域

免疫系统疾病神经系统疾病

在研适应症

免疫系统疾病神经系统疾病

非在研适应症-

原研机构

Tranquis Therapeutics, Inc.初创企业

在研机构

Tranquis Therapeutics, Inc.初创企业

非在研机构-

最高研发阶段药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Next generation compounds(Tranquis Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Next generation compounds(Tranquis Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Next generation compounds(Tranquis Therapeutics) 相关的专利（医药）

登录后查看更多信息

1

项与 Next generation compounds(Tranquis Therapeutics) 相关的文献（医药）

1992-10-01·Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry

[The effect of antipsychotic drugs on dopamine-receptors on caudate calf].

Article

作者: Guo, Q Y

Using radioligand receptor binding assay (RRA), dopamine receptor in the calf caudate were identified with 3H-Spiperone as radioactive ligand. The total number of maximal binding sites (Bmax), the equilibrium dissociation affinity (Kd), the concentrations of drug required to inhibited 50% specific binding (Ic50) and competitive inhibition constant (Ki) of antipsychotics in calf caudate were determined by sturative binding experiment and inhibitive binding experiment. The result showed the mean Bmax was 0.659 pmol/mg protein membrane and Kd was 0.31 nmol/L. Scatchard analysis denotes that it was hyperbole and there were two binding positions in calf caudte. Antipsychotics can inhibit 3H-Spiperone binding specifically the order of affinity constants (1/Ki) was Haloperdol and sulpiride, Chlorpromazine and Clozapin, Tranquis and Taractan. This abilities of drugs to compete with 3H-Spi binding will be used as basis of RRA for measuring blood levels of antipsychotics.

100 项与 Next generation compounds(Tranquis Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫系统疾病	药物发现	-	Tranquis Therapeutics, Inc.初创企业	2022-04-25
神经系统疾病	药物发现	-	Tranquis Therapeutics, Inc.初创企业	2022-04-25